Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT Predicts Bone Marrow Failure After 223Ra Therapy

Full text
Author(s):
Etchebehere, Elba C. [1, 2] ; Araujo, John C. [3] ; Milton, Denai R. [4] ; Erwin, William D. [5] ; Wendt, III, Richard E. ; Swanston, Nancy M. [1] ; Fox, Patricia [4] ; Macapinlac, Homer A. [1] ; Rohren, Eric M. [1]
Total Authors: 9
Affiliation:
[1] Univ Texas MD Anderson Canc Ctr, Dept Nucl Med, 1400 Pressler, FCT 16-6005, Unit 1483, Houston, TX 77030 - USA
[2] Univ Estadual Campinas, Dept Nucl Med, Campinas, SP - Brazil
[3] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 - USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 - USA
[5] III, Univ Texas MD Anderson Canc Ctr, Dept Imaging Phys, Houston, TX 77030 - USA
Total Affiliations: 5
Document type: Journal article
Source: CLINICAL NUCLEAR MEDICINE; v. 41, n. 4, p. 268-273, APR 2016.
Web of Science Citations: 15
Abstract

Purpose Determine if skeletal tumor burden on F-18-fluoride PET/CT (fluoride PET/CT) predicts the risk of bone marrow failure (BMF) after Ra-223 dichloride therapy (Ra-223). Methods Forty-one metastatic prostate cancer patients (43-89 years old; mean, 71 +/- 9 years.) underwent fluoride PET/CT prior to Ra-223. Bone marrow failure was the primary end point and was defined as (1) development of hematologic toxicity (World Health Organization grade 3 or 4) associated with no recovery after 6 weeks or (2) death due to BMF after the last Ra-223 dose. Bone marrow failure was correlated to fluoride PET/CT skeletal tumor burden (TLF10 {[}total lesion on fluoride PET/CT with SUVmax of 10 or greater]), use of chemotherapy, serum hemoglobin concentration, serum ALP, and serum prostate-specific antigen. Results The number of Ra-223 cycles ranged from 2 to 6 (mean, 5). Of the 41 patients, 16 developed BMF (G3 = 12; G4 = 4). A significantly increased risk of developing BMF was observed in patients with TLF10 of 12,000 or greater (hazard ratio {[}HR], 11.09; P < 0.0001), hemoglobin of less than 10 g/dL (HR, 7.35; P = 0.0002), and AP > 146 UI/L (HR, 4.52; P = 0.0100). Neither concomitant (HR, 0.91; P = 0.88) nor subsequent use of chemotherapy (HR, 0.14; P = 0.84) increased the risk of BMF, nor was prostate-specific antigen greater than 10 mu g/L (HR, 0.90; P = 0.86). Moreover, in a multivariable analysis, TLF10 was the only independent predictor of BMF (HR, 6.66; P = 0.0237). Conclusions Ra-223 was beneficial and reduced the risk of death even in patients with a high skeletal tumor burden. Fluoride PET/CT is able to determine which patients will benefit from Ra-223 and which will develop BMF. (AU)

FAPESP's process: 14/03317-8 - Fluoride-18F PET/CT to evaluate effectiveness of treatment of metastatic prostate cancer with Ra-223
Grantee:Elba Cristina Sá de Camargo Etchebehere
Support type: Scholarships abroad - Research